Dong-A Socio Holdings Co., Ltd. (KRX: 000640)

Market Cap	707.58B
Revenue (ttm)	1.29T
Net Income (ttm)	55.08B
Shares Out	6.25M
EPS (ttm)	8,811.78
PE Ratio	12.85
Forward PE	10.27
Dividend	1,900.00 (1.68%)
Ex-Dividend Date	Jun 27, 2024

Volume	21,739
Open	110,300
Previous Close	110,300
Day's Range	110,300 - 115,100
52-Week Range	93,600 - 128,500
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 31, 2025

About Dong-A Socio Holdings

Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical tri...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 5,530
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000640

Financial Performance

In 2023, Dong-A Socio Holdings's revenue was 1.13 trillion, an increase of 11.54% compared to the previous year's 1.01 trillion. Earnings were 57.99 billion, an increase of 419.96%.